aspirin has been researched along with r-138727 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Winters, KJ | 1 |
| Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Winters, KJ; Wrishko, RE | 1 |
| Armstrong, PC; Chan, MV; Jakubowski, JA; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Warner, TD | 1 |
| Amore, C; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Totani, L | 1 |
| Ikeda, Y; Kondo, K; Matsushima, N; Umemura, K | 1 |
2 trial(s) available for aspirin and r-138727
| Article | Year |
|---|---|
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aging; Aspirin; Bleeding Time; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Fasting; Female; Humans; Least-Squares Analysis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Statistics, Nonparametric; Tablets, Enteric-Coated; Thiophenes; Young Adult | 2009 |
Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects.
Topics: Adult; Area Under Curve; Aspirin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Healthy Volunteers; Humans; Japan; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Young Adult | 2017 |
3 other study(ies) available for aspirin and r-138727
| Article | Year |
|---|---|
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Humans; Inflammation; Kinetics; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis; Up-Regulation | 2007 |
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Triphosphate; Arachidonic Acid; Aspirin; Collagen; Drug Synergism; Epinephrine; Humans; In Vitro Techniques; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thromboxane A2 | 2011 |
Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Biomarkers; Blood Platelets; Disease Models, Animal; Down-Regulation; Humans; Inflammation Mediators; Leukocytes; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Piperazines; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Selenoprotein P; Shock, Septic; Thiophenes; Thromboxane B2; Tumor Necrosis Factor-alpha | 2012 |